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ABSTRACT 
 
Apolipoprotein A5 (APOA5) is a newly described member of the 
apolipoprotein gene family whose initial discovery arose from comparative 
sequence analysis of the mammalian APOA1/C3/A4 gene cluster.  Functional 
studies in mice indicated that alteration in the level of APOA5 significantly 
impacted plasma triglyceride concentrations.  Mice over-expressing human 
APOA5 displayed significantly reduced triglycerides, while mice lacking apoA5 
had a large increase in this lipid parameter.  Studies in humans have also 
suggested an important role for APOA5 in determining plasma triglyceride 
concentrations.  In these experiments, polymorphisms in the human gene were 
found to define several common haplotypes that were associated with significant 
changes in triglyceride concentrations in multiple populations.  Several separate 
clinical studies have provided consistent and strong support for the effect with 
24% of Caucasians, 35% of African-Americans and 53% of Hispanics carrying 
APOA5 haplotypes associated with increased plasma triglyceride levels. In 
summary, APOA5 represents a newly discovered gene involved in triglyceride 
metabolism in both humans and mice whose mechanism of action remains to be 
deciphered. 
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Genomics and the Identification of APOA5 
 
Recent accomplishments by the Human Genome Project have facilitated 
genome-wide strategies to uncover functional regions of the mammalian 
genome.  With the increasing availability of genomic sequences from multiple 
species, comparative genomic approaches have proven to be a powerful means 
for annotating human sequence1-5.  A basic underlying hypothesis of 
comparative genomics is that evolutionary conserved sequences are functionally 
important.  Based on this hypothesis, biological experimentation has focused on 
sequences that are highly conserved between vertebrate species.  Recently, this 
strategy was applied to the well-characterized APOA1/C3/A4 gene cluster to 
identify additional functional elements and resulted in the identification of a new 
apolipoprotein gene (APOA5)3. 
 
While the human APOA1/C3/A4 gene cluster sequence has long been 
available, the recent generation of the orthologous mouse sequence provided a 
comparative-based method of analyzing the human interval (Figure 1).  In 
addition to the extensive evolutionary conservation of human/mouse exons in 
the region, several non-coding conserved elements were also uncovered.  The 
largest of these sequences was located ~30 kb downstream of APOA4 and 
spanned several thousand basepairs with a high percent identity between 
humans and mice.  These striking features prompted further analyses of the 
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interval3.  Experimental studies with sequences from this region indicated the 
interval was transcribed in liver tissue from both humans and mice and 
suggested this was a previously unappreciated gene.  Closer examination of the 
genomic sequence alignment predicted four exons in both species with a highly 
conserved open reading frame.  Translation of this sequence revealed high levels 
of protein identity with APOAIV, the neighboring genes' product.  This 
paralogous relationship resulted in the naming of this newly identified gene as 
"APOA5"3.   These studies further highlight the utility of comparative genomic 
approaches and led to the further characterization of this newly identified gene. 
 
APOA5 is located within the previously well-defined APOA1/C3/A4 gene 
cluster on human chromosome 11q23 and in an orthologous block of mouse 
chromosome 96-8.  Numerous studies support the concept that members of the 
apolipoprotein gene family arose by gene duplication events9,10; though the 
precise evolutionary events leading to the present day cluster are not 
understood.  The finding that this four-member apolipoprotein gene cluster is 
present in both humans and mice indicate that the evolutionary duplication 
events predate the last common ancestor of these two mammalian species11.  It is 
worth noting that recent studies in our laboratory have identified the same 
organization of this gene cluster in the chicken genome, further supporting the 
original gene duplication events were prior to the mammalian/avian 
evolutionary split (Pennacchio and Rubin, unpublished data, 2002). 
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 Amino acid analyses of APOAV show a high level of sequence identity 
between human, mouse and chicken (Figure 2A).  For instance, human and 
mouse APOAV display 71% amino acid identity and 78% similarity (Figure 2B).  
The length of the proteins are also similar and are composed of 366, 368 and 355 
amino acids in human, mouse and chicken, respectively.  These lengths are 
slightly shorter than those for APOAIV in these species which are 396, 394, and 
366 amino acids, respectively.  Sequence alignment and phylogenetic analysis 
indicates a closer sequence relationship among APOAV in humans, mice and 
chicken compared to APOAIV from any of these species (Figure 2C).  Again, this 
supports an ancient duplication event(s) that predates the last common ancestor 
of mammals and birds. 
 
A unique feature of APOA5 compared to its evolutionary-related 
apolipoprotein paralogs is its multiple transcripts of approximately 1.3- and 1.9-
kilobases as determined by Northern blot analysis11.  Alternative transcripts have 
not been described for other members within this gene cluster.  Examination of 
expressed sequence tags in Genbank indicates the two transcripts are the result 
of alternative polyadenylation.  The functional relevance, if any, of these two 
transcripts remains to be uncovered. 
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 It is worth noting that APOA5 was also identified in rats where it was 
found to be up-regulated following liver regeneration12.  In this work, 
differentially expressed genes were identified six hours after a 70% rat 
hepatectomy.  Based on the feature of being the most highly over-expressed 
gene, it was independently named "Regeneration Associated Protein 3 (RAP3)" 
and was proposed to be important in the early phase of liver regeneration. 
 
 
 
 
Genetically Engineered Mice Reveal a Role for APOA5 in Triglyceride Homeostasis 
 
The sequence similarity between APOAV and other apolipoproteins suggested 
that APOAV functions in the plasma with a role in lipid transport11.  Indeed, 
structural predictions indicate that APOAV contained a signal peptide export 
sequence for transport from the liver to plasma, and that the mature APOAV protein 
contains several amphipathic helical domains11,13-15.  These motifs are characteristics 
of lipid binding molecules and are generally present in apolipoproteins. 
 
To define the true in vivo function of APOA5, two different engineered mouse 
lines were generated11.  First, a human 26kb XhoI restriction fragment was isolated 
that was predicted to contain only APOA5 and its' flanking sequence.  This genomic 
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piece of DNA was subsequently used to generate human APOA5 transgenic mice 
("APOA5 over-expressors").  Second, the endogenous mouse apoA5 gene was deleted 
from the mouse genome ("apoA5 knockouts") through standard embryonic stem cell 
technology.  Examination of plasma lipid levels in both APOA5 "over-expressors" 
and "knockouts" revealed profound effects on triglyceride concentrations.  
Specifically, APOA5 transgenics displayed a 66% decrease in triglycerides.  In 
contrast, apoA5 knockouts had four-fold higher triglycerides than controls.  In both 
models consistent changes in APOB and very low-density lipoprotein (VLDL) 
particle quantities were noted, though no differences were seen in plasma- or HDL-
cholesterol levels. 
 
 Recent studies in mice using adenoviral vectors containing APOA5 confirmed 
the strong effect of over-expressing APOA5 on plasma triglyceride levels16.  In this 
work, the authors estimate ~20-fold higher plasma APOAV levels in vector treated 
animals and observed an ~70% reduction in plasma triglyceride concentrations, 
similar to that in the original APOA5 transgenic report11.  Interestingly, while these 
two independent over-expressing lines both showed an~70% reduction in 
triglycerides, the adenoviral treated mice also had a 40% reduction in plasma 
cholesterol levels, a lipid parameter not previously noted to change in response to 
alterations in APOA5 levels in mice.  It is possible that the extremely high level of 
APOAV in the adenoviral treated mice creates an artificial condition that accounts for 
this novel finding. 
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These studies in mice provide convincing evidence that APOAV plays a role in 
plasma triglyceride homeostasis.  The triglyceride lowering effect of APOAV is quite 
distinct from the impact of several other apolipoprotein transgenes (APOCI , CII, 
CIII, APOB) where increased protein levels led to higher triglyceride levels17-19.  The 
mechanism by which alterations in APOAV impact on triglyceride concentrations 
remains to be deciphered. 
 
Some clues to the function of APOAV have been suggested based on the 
computational analysis of the proteins' amino acid sequence.  A direct 
comparison with human APOAIV indicates that APOAV has a higher global 
hydrophobicity, contains a greater amount of α-helical structure, and is 
predicted to have a higher interfacial exclusion pressure (Weinberg, unpublished 
data, 2002).  This suggests that APOAV should display a very high affinity for 
lipid interfaces.  It has been proposed that apolipoproteins with moderate lipid 
affinity and high elasticity, such as APOAIV, facilitate triglyceride-rich particle 
assembly by stabilizing nascent particles as they acquire triglyceride and expand 
in the second stage of assembly20,21.  Conversely, apolipoproteins with very high 
lipid affinity, such as APOAV, could impede this process, thereby functioning as 
an intracellular "brake" on hepatic lipid export.  Functional studies are needed to 
test this hypothesis. 
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Association Studies Extend APOA5's Role in Triglyceride Homeostasis to Humans 
 
The experimental studies described thus far provide convincing evidence 
for APOAV's role in plasma triglyceride homeostasis in mice.  These findings 
suggested that sequence alterations in the human APOA5 gene might also 
contribute to differences in plasma lipid levels in humans.  To date from 
extensive resequencing of the APOA5 gene, severe mutations in humans have 
not been reported.  However, several studies have consistently showed that 
common genetic variations mapping to the human APOA5 locus in humans are 
strongly associated with quantitative differences in plasma triglyceride levels of 
normolipidemic individuals in the general population.  A detailed description of 
APOA5 polymorphisms, the haplotypes they define, and the various genetic 
associated studies are provided below. 
 
APOA5 Polymorphism Identification and Haplotype Analysis 
 
Extensive sequencing of the APOA5 interval in humans has been 
performed in several studies to identify common polymorphisms for subsequent 
genetic association studies11,22.  Initially, a set of four common polymorphisms 
(SNPs1-4, also named c.1259T>C, IVS3+476G>A, -1131T>C and -12,238T>C, 
respectively) were identified within the human APOA5 interval.  Statistical 
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analysis indicated that the minor alleles of SNPs1-3 formed a relatively common 
haplotype which is found in ~15% of Caucasians11,22.  
 
Subsequently, a more exhaustive screen for APOA5 polymorphisms was 
undertaken22.  Through the direct DNA sequencing of the gene in 116 
hyperlipidemic individuals, nine additional SNPs were identified.  One of the 
polymorphisms (c.-3A>G) was found to be in strong linkage disequilibrium with 
the minor alleles for SNPs1-3 and this haplotype was named "APOA5*2".   In 
addition, a second common polymorphism was also identified which results in a 
C to G nonsynonymous substitution (c. 56C>G) changing codon 19 from serine to 
tryptophan.  Further haplotype analysis in Caucasians indicated that the minor 
allele of this polymorphism defines a third common APOA5 haplotype 
(APOA5*3).  Similar to APOA5*2, this haplotype was also found in ~15% of 
Caucasians.  The remaining seven polymorphisms from this study were either 
uncommon or not obviously associated with triglycerides22.  
 
 Thus, polymorphism discovery and haplotype analysis in Caucasians 
defined three common haplotypes in the APOA5 interval and provided detailed 
information for genetic association studies in humans.  In these analyses, the -
1131C allele (SNP3) was used as a marker to define APOA5*2, while the c.56G 
allele (W19) was used to define APOA5*322.  Studies of these two minor alleles 
indicated that they are also present at a high frequency in African-Americans and 
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Hispanics and support that these polymorphisms arose early in the evolutionary 
history of humankind. 
 
Berkeley Lipid Study Population 
 
The initial genetic association study with markers that defined APOA5*2 
and APOA5*3 was performed in 500 random unrelated normo-lipidemic 
Caucasian individuals11,22.  Strong associations were found between these two 
minor haplotypes and increased triglyceride concentrations (Figure 3).  
Specifically, each of these haplotypes was associated with a ~30% increase in 
triglyceride concentrations compared to individuals lacking the minor alleles 
that define APOA5*2 and APOA5*3.   Similar association was also found for the 
related plasma parameter VLDL mass.  Further studies in these 500 individuals 
found no significant association of triglyceride levels with a Sst1 polymorphism 
in APOC3 (located ~40 kbp upstream of APOA5) which has been previously 
associated with severe hyper-triglyceridemia23-34.  This finding supports that 
these APOA5 haplotypes are associated with altered triglyceride levels 
independent of the APOC3 Sst1 polymorphism. 
 
Stratified Population Study 
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As a follow-up to the initial association, an independent Caucasian 
population was examined using a different experimental design11,22.  In this 
study, the allele frequencies of -1131T>C (SNP3; APOA5*2) and c.56C>G (S19W; 
APOA5*3) were compared in an unrelated group of Caucasians stratified 
according to plasma triglyceride levels.  The two groups represented 1) several 
hundred individuals with triglyceride levels in the top tenth-percentile and 2) 
several hundred individuals with triglyceride levels from the bottom tenth-
percentile of a larger population.  For both polymorphisms, an approximately 
three-fold over-representation of the minor alleles was found in individuals from 
the high- versus low-plasma triglyceride group. 
 
The Dallas Heart Disease Prevention Program 
 
Recently, a third study tested for genetic association between APOA5 and 
triglycerides in ethnic groups beyond Caucasians22.  The Dallas population 
studied comprised ~2600 randomly selected individuals representing African-
Americans and Hispanics, in addition to Caucasians.  Once again, strong genetic 
associations were found between both the -1131T>C and c.56C>G 
polymorphisms and triglycerides.  For c.56C>G (APOA5*3), the effect was seen 
in both men and women from each ethnic group.  While for c56.C>G (APOA5*2), 
increased plasma triglyceride concentrations were found in Hispanic men and 
women, and in Caucasian men, but not in African-American men and women or 
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in Caucasian women.  Whether the lack of an association in this subset of 
samples is due to a small sample size or significant gender- and ethnic-specific 
effects remains to be determined. 
 
Northwick Park Heart Study (NPHSII) 
 
In addition, a detailed genetic analysis was performed with several 
polymorphisms within the APOA1/C3/A4 cluster as well as APOA535.  In 2800 
Caucasian males, individuals homozygous for APOA5 19W (APOA5*3) or SNP3 
(-1131C; APOA5*2) had 52% and 40% higher triglycerides (p < 0.003) compared 
to individuals homozygous for the common allele, respectively.  Further 
examination of a SNP (T347S) in the neighboring APOA4 gene indicated that 
347SS men had 23% lower triglycerides than 347TT men.  Statistical analyses of 
these SNPs and four APOC3 SNPs (-2845T>G, -482C>T, 1100C>T, and 3238C>G) 
revealed that the effects of APOA5 S19W (p<0.0001), APOC3 –482C>T (p<0.002) 
and APOA4 T347S (p<0.007) most significantly accounted for the triglyceride 
differences in this male population.  Additional haplotype analysis defined the 
triglyceride-raising alleles as being APOA5 W19 and APOC3 –482T.   The 
conclusion from this study was that variation in both APOA5 and APOA4, in 
addition to effects previously reported for APOC3, are associated with 
differences in triglycerides in healthy men. 
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Japanese School Children Study 
 
 In a final normo-lipidemic population study, Japanese school children 
were examined for association between APOA5 SNP3 (-1131C; APOA5*2) and 
triglycerides36.  Once again, higher triglyceride levels (~15%) were found in 
individuals containing minor alleles for SNP3 compared to those homozygous 
for the major allele.  This study supports an age-independent effect of APOA5 
polymorphisms on plasma triglyceride concentrations and further extends its' 
affect to an additional ethnic group.  Of additional significance is the extremely 
high population frequency of the SNP3 minor allele in the Japanese.  In this 
work, 61% of individuals contained at least one copy of the SNP3 minor allele, in 
comparison to the 15%, 30% and 22% found in Caucasians, Hispanics, and 
African-Americans, respectively.  The c.56C>G (APOA5*3) polymorphism was 
not examined in this population. 
 
APOA5 and Familial Combined Hyperlipidemia 
 
 In addition to genetic studies in the general normo-lipidemic population, 
studies have also been performed in individuals with abnormal plasma lipid 
levels.  A common disorder of lipid metabolism in humans is combined 
hyperlipidemia (CHL) which is characterized by increased triglycerides and/or 
cholesterol and leads to an increased risk of cardiovascular disease.  The severe 
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triglyceride phenotype in this complex condition suggested that APOA5 might 
contribute to the disease etiology. 
 
 To test whether variation at the APOA5 locus contributes to the transmission 
of CHL, linkage and linkage disequilibrium (LD) tests were performed on a large 
cohort of families (n=128) with familial CHL (FCHL).  Indeed, the linkage data 
produced evidence for linkage of the APOA1/C3/A4/A5 genomic interval to FCHL 
(NPL = 1.7, P = 0.042).   Further studies revealed that two independent rare 
alleles, APOA5 19W (c.56G) and the nearby APOC3 c.386G were over-transmitted 
in FCHL (P = 0.004 and 0.007, respectively).  The APOA5 19W allele was 
associated with increased plasma triglycerides in FCHL probands, while in 
contrast the second and independent APOC3 c.386G allele was associated with 
increased plasma triglyceride levels in FCHL pedigree founders. This study 
supported that common polymorphism in the APOA1/C3/A4/A5 gene cluster 
contributes to the transmission of FCHL in a substantial proportion of affected 
families. 
 
 In a second independent study, a single APOA5 polymorphism (SNP3; -
1131T>C) was examined in a set of 16 FCHL families37.  These families 
represented 42 FCHL individuals and 61 first-degree relative controls.  Analysis 
of both groups combined indicated 45% higher triglycerides in individuals 
containing the -1131C allele (1.82 mmol/L) compared to those lacking it (1.26 
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mmol/L).  In addition, the minor allele was nearly three-fold more common in 
the FCHL group compared to controls.  Again, these data support that 
polymorphism in the APOA5 interval contributes to FCHL. 
 
Summary of Human Genetic Studies 
 
These findings establish that the APOA5 locus contributes significantly to 
inter-individual variation in plasma triglyceride levels in the general human 
population.  Together, the APOA5*2 and APOA5*3 haplotypes are found in 25 to 
50 percent of African-Americans, Hispanics, and Caucasians, highlighting the 
large fraction of individuals with increased triglycerides solely due to the effect 
of APOA5 polymorphisms.  In addition to the strong effect of APOA5 haplotypes 
on plasma triglycerides from various age-, gender- and ethnic- groups, these 
chromosomal regions also appear to be important contributors to the common 
condition of FCHL. 
Functional Cause of the APOA5 Genetic Association? 
 
Genetic association studies between APOA5 polymorphisms and 
triglyceride levels have provided convincing evidence for a relationship between 
these two parameters.  However, it remains unclear which variant(s) in the 
APOA5 chromosomal region are responsible for this association.  While 
functional studies are needed to definitely prove the culprit variant(s), there is a 
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single strong candidate within each of the minor haplotypes (APOA5*2 and 
APOA5*3) associated with triglyceride levels22. 
 
APOA5*2 is composed of several minor alleles that extend throughout the 
APOA5 gene.  One of these polymorphisms (c.-3A>G) is found three basepairs 
upstream of the predicted start codon for APOA5 in a functionally important 
base of the putative Kozak consensus sequence38-40.  The compilation of 
numerous vertebrate gene sequences upstream of the start codon indicates a 
strong bias in the consensus base at the -3bp position with the nucleotide A being 
found in 61% of cases39.  Thus, the c.-3A>G polymorphism which changes the 
common allele A to G at -3bp could potentially result in a decreased rate of 
APOA5 mRNA translation and thereby lead to lower APOAV plasma levels.  
Mechanistically, this result would be consistent with the finding of increased 
triglycerides in mice lacking apoA5 ("apoA5 knockouts")11. 
 
In contrast to APOA5*2, APOA5*3 is defined by a single minor allele 
within the APOA5 coding sequence.  The c.56C>G sequence variant results in a 
non-conservative change of serine to tryptophan at codon 19.  Apolipoproteins 
and other polypeptides that function in plasma are known to contain N-terminal 
export signal sequences.  Indeed, computational analyses for APOAV predict a 
strong export consensus sequence with a likely export cleavage site between 
amino acids 23 and 2441.  The change of a serine to a bulky tryptophan residue at 
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position 19 could thus reduce the rate of APOAV export from the liver and result 
in higher triglycerides in humans. 
 
 
Future Perspectives 
 
The large generation of DNA sequence by the Human Genome Project has 
accelerated our discovery of new genes.  This is readily apparent in the discovery 
of APOA5 through the use of publicly available genomic sequence surrounding 
the APOA1/C3/A4 gene cluster in humans and mice11.  Based on this success 
should we expect that other members of the mammalian apolipoprotein gene 
family remain to be discovered?  While possible, the answer is unlikely.  
Currently, sequence for the vast majority of the human genome is available and 
electronic searches for additional evolutionarily-related apolipoprotein 
sequences have failed to uncover additional family members.  With that as it 
may, why was APOA5 previously missed in the well-studied area of plasma 
apolipoproteins?  Part of the explanation may be due to the neighboring gene 
and paralogous relationship between APOA4and APOA5.  These features may 
have shielded their view and made these two separate gene appear like one.  The 
low levels of APOAV in mammalian plasma may also have contributed to its' 
lack of earlier discovery. 
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 A striking feature of APOA5 is its' strong effect on triglyceride levels in 
both humans and mice.  It is clear that alterations in APOA5 levels in mice are 
inversely correlated with triglyceride levels.  In addition to these mouse studies, 
common human sequence variation in APOA5 has also been significantly 
associated with triglyceride levels in the general population.  Surprisingly, the 
minor APOA5 haplotypes associated with increased triglycerides are found in 
~25-50 % of Caucasians, African-Americans, and Hispanics indicating their wide-
reaching effects.  These findings support the concept that common genetic 
variation contributes to common quantitative phenotypes in the general 
population.  This holds promise for future genome-wide association strategies 
aimed at uncovering common genetic contributors to quantitative and disease 
phenotypes in humans.  Future experimentation will determine if the significant 
increase in plasma triglyceride levels translates into an increased risk for 
cardiovascular disease and the specific mechanisms by which APOAV impacts 
on this important plasma lipid parameter. 
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FIGURE LEGENDS 
 
FIGURE 1. Human, mouse and rabbit comparative sequence analysis of the 
APOA1/C3/A4/A5 gene cluster.  In each panel 30 kb of contiguous human 
sequence is illustrated horizontally.  Above each panel arrows correspond to 
known genes and their orientation with each exon depicted by a box (gene 
names are indicated above each arrow).  Dark blue boxes represent coding 
regions of exons and light blue boxes untranslated regions.  The VISTA graphical 
plot displays the level of homology between human and the orthologous mouse 
sequence in the top portion and between human and rabbit in the bottom portion 
of each panel (http://pga.lbl.gov)42.  Human sequence is represented on the x-axis 
and the percent similarity with the mouse or rabbit sequence is plotted on the y-
axis (ranging from 50-100% identity).  Blue shading indicate conserved exon 
sequences and red shading highlights conserved noncoding sequences.  The 
APOA5 gene was identified ~30 kb downstream of APOA4 based on its high 
level of conservation between humans and mice. 
 
FIGURE 2. Computational analyses of the human, mouse and chicken APOAV 
proteins. (A) Amino acid sequence alignment of the human, mouse and chicken 
APOAV proteins. (B) Amino acid percent similarity and identity between the 
human, mouse and chicken APOAV proteins. (C) Phylogenetic relationships of 
the human, mouse and chicken APOAV and APOAIV proteins. 
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FIGURE 3. Plasma triglyceride concentrations in a random sample of ~500 
normo-lipidemic Caucasians separated by APOA5 genotype (Berkeley Lipid 
Study Population)22.  The APOA5*2 and APOA5*3 haplotypes were defined by 
the -1131C and c. 56G minor alleles, respectively. 
